Cemiplimab as Second-Line Therapy for Patients with Recurrent Cervical Cancer: A United States-based Cost-effectiveness Analysis

[1]  I. Ray-Coquard,et al.  Recurrent or primary metastatic cervical cancer: current and future treatments , 2022, ESMO open.

[2]  B. Monk,et al.  519MO Phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial of cemiplimab in recurrent or metastatic (R/M) cervical cancer: Long-term survival analysis , 2022, Annals of Oncology.

[3]  I. Vergote,et al.  EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer. , 2022, European journal of cancer.

[4]  B. Monk,et al.  Survival with Cemiplimab in Recurrent Cervical Cancer. , 2022, The New England journal of medicine.

[5]  Wanqing Chen,et al.  Cancer statistics in China and United States, 2022: profiles, trends, and determinants , 2022, Chinese medical journal.

[6]  Chinmoy K. Bose.  Balstilimab and other immunotherapy for recurrent and metastatic cervical cancer , 2022, Medical Oncology.

[7]  Yang Shi,et al.  Cost-effectiveness analysis of pembrolizumab for treatment of US patients with persistent, recurrent, or metastatic cervical cancer. , 2021, Gynecologic oncology.

[8]  B. Monk,et al.  Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. , 2021, The New England journal of medicine.

[9]  Jin Huang,et al.  Cost-Effectiveness Analysis of Durvalumab Plus Chemotherapy in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[10]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[11]  M. Amonkar,et al.  Cost-effectiveness of pembrolizumab compared with chemotherapy in the US for women with previously treated deficient mismatch repair or high microsatellite instability unresectable or metastatic endometrial cancer , 2021, Journal of medical economics.

[12]  Sung-Bae Kim,et al.  Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  A. Jazaeri,et al.  Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). , 2020, Gynecologic oncology.

[14]  Chongqing Tan,et al.  Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis , 2019, Clinical Drug Investigation.

[15]  D. Carbone,et al.  Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater. , 2019, Lung cancer.

[16]  K. Syrigos,et al.  Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. , 2019, The New England journal of medicine.

[17]  E. Jordanova,et al.  Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix , 2016, Modern Pathology.

[18]  J. Java,et al.  Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in gynecologic oncology group trials of cisplatin-based chemoradiation. , 2014, Gynecologic oncology.

[19]  Chunlin Chen,et al.  The efficacy of neoadjuvant chemotherapy in different histological types of cervical cancer. , 2014, Gynecologic oncology.

[20]  B. Monk,et al.  Chemotherapy-induced neutropenia as a biomarker of survival in advanced ovarian carcinoma: an exploratory study of the gynecologic oncology group. , 2014, Gynecologic oncology.

[21]  Michael W Sill,et al.  Improved survival with bevacizumab in advanced cervical cancer. , 2014, The New England journal of medicine.

[22]  Ting Hu,et al.  Changes in prevalence and clinical characteristics of cervical cancer in the People's Republic of China: a study of 10,012 cases from a nationwide working group. , 2013, The oncologist.

[23]  B. Monk,et al.  Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  B N Bundy,et al.  Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  B N Bundy,et al.  Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. , 1999, The New England journal of medicine.

[26]  K. Blank,et al.  Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer , 1999 .